The Australian medical landscape is abuzz with the introduction of retatrutide, a novel dual GIP and GLP-1 receptor agonist showing significant results in early trials for managing obesity. This https://bookmarkbooth.com/story21794394/retatrutide-australia-australia-a-emerging-prospect-for-weight-loss